---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-285351"
form_type: "8-K"
ticker: "AXTA"
cik: "0001616862"
company_name: "Axalta Coating Systems Ltd."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:47:52.871022+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Axalta and AkzoNobel sign all-stock merger of equals; Axalta shareholders to receive 0.6539 AkzoNobel shares each

## Summary
- Exchange ratio of 0.6539 AkzoNobel ordinary shares per Axalta ordinary share; AkzoNobel to pay €2.5B special dividend pre-close.
- MergeCo to be dual-headquartered in Amsterdam and Philadelphia; listed on NYSE and Euronext Amsterdam.
- Chris Villavarayan (Axalta CEO) to be deputy CEO; Grégoire Poux-Guillaume (AkzoNobel CEO) to be CEO; Rakesh Sachdev to be non-executive chair.
- Mutual termination fee of €150M payable under specified circumstances; outside date May 18, 2027 (extendable to Nov 18, 2027).
- Conditions include Axalta and AkzoNobel shareholder approvals, HSR and other regulatory clearances, and effectiveness of Form F-4.

## SEC filing metadata
- accession: 0001193125-25-285351
- form_type: 8-K
- ticker: AXTA
- cik: 0001616862
- company_name: Axalta Coating Systems Ltd.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1616862/000119312525285351/0001193125-25-285351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1616862/000119312525285351/d45746d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-285351
- JSON: https://secwatch.observer/filing/0001193125-25-285351.json
- Plain text: https://secwatch.observer/filing/0001193125-25-285351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.